Exhibit 99.1
Dr. Reddy's Laboratories Ltd. | |
8-2-337, Road No. 3, Banjara Hills, | |
Hyderabad - 500 034, Telangana, | |
India. | |
CIN : L85195TG1984PLC004507 |
Tel | :+91 40 4900 2900 | |
Fax | :+91 40 4900 2999 | |
:mail@drreddys.com | ||
www.drreddys.com |
May 20, 2020
Corporate Relationship Department | National Stock Exchange of India Ltd. |
BSE Limited | "Exchange Plaza" |
Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
Mumbai – 400 001 | Mumbai – 400 051 |
Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
22722037 /22722039 | 26598238 |
Scrip Code: 500124 | Scrip Code: DRREDDY-EO |
Dear Sirs,
Sub: Intimation
Further to our intimation dated February 28, 2020 with regard to the audit of our Formulations Manufacturing Plant – 3 at Bachupally, Hyderabad, we would like to inform you that we have received the Establishment Inspection Report (EIR) from US FDA, for the above-referred facility, indicating closure of the audit.
This is for your information.
With regards, | |
/s/ Sandeep Poddar | |
Sandeep Poddar | |
Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)